anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lung cancer is a leading cause of mortality worldwide, and its treatment and prognosis are being revolutionized by immunotherapy. The gut microbiome has been shown able to modulate the antitumor efficacy of immunotherapeutic agents in pre-clinical models, demonstrating that patients can be stratified into responders and nonresponders to immunotherapy on the basis of their microbiota composition. Fecal microbiota transplants have demonstrated to improve the efficacy of immunotherapy in animal models. In this study, investigators will include 20 stage III/V non-small cell lung cancer naïve for PD/PD L-1 inhibitors that require treatment in monotherapy or combined with chemotherapy as consolidation strategy after concurrent chemotherapy and radiotherapy (stage III), upfront treatment (stage IV patients with PDL1 status \> 50%) or as second line strategy for those patients with advanced disease who progressed to chemotherapy alone. The participants will be randomized to receive either fecal microbiota capsules from 3 donors selected based on the fecal abundance of bacterial taxa shown to correlate with a greater response to immunotherapy or not, in combination with the PDL/PDL1 agent. The primary outcome will be safety. The secondary outcomes will be treatment response (iRECIST criteria). Investigators will also examine engraftment of donor's microbiota on host microbiota using Illumina DNA shotgun sequencing, changes in the bacterial metabolism using metaproteomics, and in the plasma metabolite fingerprint by untargeted mass spectrometry in bacterial and plasma samples, and changes in peripheral immune cells subpopulations and antitumoral immunity. MORELIA could improve the prognosis of a lung cancer in a subset of patients with limited therapeutic options and inform on how to exploit host-microbiota interactions with tailored fecal microbiota transplantation to boost the clinical response to immunotherapy in advanced cancer.
Patients with chronic kidney disease (CKD) often experience mild cognitive impairment and other neurocognitive disorders. Studies have shown that erythropoietin (EPO) and its receptor have neuroprotective effects in cell and animal models of nervous system disorders. Recombinant human EPO (rHuEPO), commonly used to treat anemia in CKD patients, could be a neuroprotective agent. In this systematic review, we aimed to assess the published studies investigating the cognitive benefits of rHuEPO treatment in individuals with reduced kidney function. We comprehensively searched Pubmed, Cochrane Library, Scopus, and Web of Science databases from 1990 to 2023. After selection, 24 studies were analyzed, considering study design, sample size, participant characteristics, intervention, and main findings. The collective results of these studies in CKD patients indicated that rHuEPO enhances brain function, improves performance on neuropsychological tests, and positively affects electroencephalography measurements. These findings suggest that rHuEPO could be a promising neuroprotective agent for managing CKD-related cognitive impairment.
Oral Lenalidomide 10 mg/day started on Day 9 of cycle 1; Rituximab 375 mg/m\^2 intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2. Treatment duration twelve cycles.
Pneumococcus is the most common bacterial opportunistic infection in HIV-infected children, and it is the leading cause of bacterial pneumonias in HIV-infected pregnant and non-pregnant adults. Pneumococcal polysaccharide vaccine (PPV-23) and pneumococcal conjugate vaccine (PCV-13) are two vaccines used for the prevention of pneumococcal (PNC) disease. The PPV-23 vaccine is recommended by the Centers for Disease Control and Prevention (CDC) for HIV-infected adults, including HIV-infected pregnant women. The PCV-13 vaccine is recommended by the CDC for use in children, including HIV-infected children. Studies have shown that PCV-13 and vaccines like PCV-13 are safe for use in healthy pregnant women, but they have not been studied in HIV-infected pregnant women. This study will compare the safety and immune response to the PCV-13 and PPV-23 vaccines in HIV-infected pregnant women.

This study will enroll HIV-infected pregnant women in their second or third trimester who are receiving antiretroviral therapy. The study will take place in two steps. In Step 1, participants will be randomly assigned to receive PPV-23 vaccine, PCV-13 vaccine, or placebo vaccine. At a baseline study visit, participants will undergo a physical examination, medical history and nutritional status review, fetal heart rate measurement, blood collection, an ultrasound, an adherence questionnaire, and a nose and throat swab procedure. They will then receive their assigned vaccine. Participants will not be told which vaccine they are receiving. Participants will remain in the clinic for 30 to 60 minutes after receiving the vaccine for monitoring. They will attend study visits 14 to 21 days after the vaccination visit, at Week 8, and at the time of labor and delivery. During these visits, they will undergo select baseline study procedures. After delivery, participants' babies will have a physical examination and blood collection. At 2 and 4 months after delivery, participants' babies will undergo select baseline study procedures. Participants' babies will receive the PCV vaccine according to the local standard of care.

Step 2 of the study will begin 6 months after delivery, at which time participants and their babies will attend a study visit for a physical examination, medical history and nutritional status review, an adherence questionnaire, and blood collection. Participants who received the PPV-23 vaccine or the PCV-13 vaccine in Step 1 will end their participation in the study after this visit. Participants who received placebo vaccine in Step 1 will be randomly assigned to receive the PPV-23 vaccine or PCV-13 vaccine at this study visit but will not be told which vaccine they are receiving. Participants will attend a study visit 14 to 21 days after receiving the vaccine, which will include select study procedures.
\[Note: As of 2/28/2001, due to toxicity studies and concerns for safety, sites were notified that they need to discontinue patients from the capravirine/placebo arms and continue patients with their background therapies or switch patients to new therapies, as deemed appropriate by the investigators.\] Patients are randomized to receive Viracept plus Combivir plus either AG1549 or placebo. Patients remain on their assigned therapy for 48 weeks with one post-therapy follow-up visit. Blood samples are taken regularly to quantify plasma HIV-1 RNA, CD4 and CD8 counts, and peripheral blood mononuclear cells (PBMC). Physical exams, safety assessments, and other tests are also done throughout the study. A blood sample is taken at baseline (pre-dose) for a pharmacokinetics assessment. On Day 8 and at the end of Weeks 4, 8, 16, 24, 36, and 48, pharmacokinetic sampling is done prior to dosing and between 2 to 4 hours post-dose.
BACKGROUND: Large language models have been gaining tremendous popularity since the introduction of ChatGPT in late 2022. Perioperative pain providers should leverage natural language processing (NLP) technology and explore pertinent use cases to improve patient care. One example is tracking persistent postoperative opioid use after surgery. Since much of the relevant data may be 'hidden' within unstructured clinical text, NLP models may prove to be advantageous. The primary objective of this proof-of-concept study was to demonstrate the ability of an NLP engine to review clinical notes and accurately identify patients who had persistent postoperative opioid use after major spine surgery.
METHODS: Clinical documents from all patients that underwent major spine surgery during July 2015-August 2021 were extracted from the electronic health record. The primary outcome was persistent postoperative opioid use, defined as continued use of opioids greater than or equal to 3 months after surgery. This outcome was ascertained via manual clinician review from outpatient spine surgery follow-up notes. An NLP engine was applied to these notes to ascertain the presence of persistent opioid use-this was then compared with results from clinician manual review.
RESULTS: The final study sample consisted of 965 patients, in which 705 (73.1%) were determined to have persistent opioid use following surgery. The NLP engine correctly determined the patients' opioid use status in 92.9% of cases, in which it correctly identified persistent opioid use in 95.6% of cases and no persistent opioid use in 86.1% of cases.
DISCUSSION: Access to unstructured data within the perioperative history can contextualize patients' opioid use and provide further insight into the opioid crisis, while at the same time improve care directly at the patient level. While these goals are in reach, future work is needed to evaluate how to best implement NLP within different healthcare systems for use in clinical decision support.
The distinction between separate primary lung carcinomas (SPLCs) and intrapulmonary metastases (IPMs) is crucial to accurate cancer staging. Histopathology-based classification cannot always determine the relatedness of multiple tumors taken from the lung. Recently, next-generation sequencing (NGS) has been used for biomarker determination, but it also has the potential to inform clonality determination among multiple tumors. Here we present a patient with three lung tumors, each diagnosed as adenocarcinoma by histopathology with a differential diagnosis of SPLC versus IPM. We pursued molecular profiling by NGS, which revealed three unique mutational patterns ruling out the possibility of clonal relatedness among the cancers. Our case supports the utility of NGS in supplementing histopathological methods to distinguish between SPLCs and IPMs and to guide treatment decisions.
Anti-inflammatory Spirothiazolidines are of formula (I) and non-toxic salts. (where X = H, halogen, esp. Cl or F, lower alkyl or alkoxy). The compounds are prepared according to the following reaction scheme: The first stage of the reaction is effected in acetone in the presence of K2CO3. The second stage is effected in an aromatic solvent, esp. benzene or toluene, at the reflux, removing the water formed as an azeotrope.
PURPOSE: To obtain an assay that is safe, reliable, effective, reproducible, and sensitive regarding detection by adsorbing pseudorabic virus antigen onto each latex particle physically or bonding covalently. CONSTITUTION: In latex composition, pseudorabic virus antigen is adsorbed physically on each latex particle or is subjected to covalent bonding. The pseudorabies virus antigen is a product of the tentative pseudorabies virus that is totally damaged or solubilized and is immunologically reacted with the pseudorabies antibody selectively. The weight ratio of the damaged and solubilized pseudorabic virus product versus latex particle ranges from approximately 1:30 to approximately 1:200. Latex polymer is used for the latex carrier particle. The latex polymer is non-aqueous, has a particle diameter ranging from 0.05-2.0 micron, and has a specific gravity closer to water so that it remains in water-based suspension state, and is inactive regarding the immunological reaction. Preferably, for example, carboxyl polystyrenes are used.
This arm will receive oral lactulose as per treatment protocol for hepatic encephalopathy i.e. 30ml twice daily. And will receive tap water enema as placebo i.e. 1000ml tap water enema twice daily.
Water stress affects the metabolic regulation and delays the growth and development of alfalfa, causing a reduction in biomass. New alfalfa germplasm was created with improved drought tolerance in greenhouse conditions by introducing the key gene P5CDH1 from C. songorica, a xerophytic grass. However, the field adaptability and response mechanism of new drought-tolerant alfalfa germplasms under water stress are still unclear. In the present study, the yield and quality traits of transgenic CsP5CDH1 alfalfa lines under water stress and normal irrigation conditions were measured and analyzed for two years. The genetic variance components of the tested traits were calculated from the data fitted by the mixed linear model. The plant height of all lines showed significant genotypic variation (σ2g) (P < 0.05), and the stem diameter, stem number, and dry weight of all lines had a significant genotype × environment interaction (σ2ge) (P < 0.05). The heritability (H) of plant height, stem diameter, stem number, dry weight and leaf-to-stem ratio of alfalfa lines were 0.87, 0.52, 0.59, 0.52 and 0.50, respectively. There were significant genotype × environment interactions (σ2ge) (P < 0.05) for the quality traits of all lines. The heritabilities (H) of acid detergent fiber and neutral detergent fiber were 0.65 and 0.64, respectively. The results of transcriptional expression analysis with RNA-seq showed that the genes MsProDH1, MsProDH4, MsProDH5, MsP5CDH1, MsP5CS5, MsP5CS9, and MsP5CR1, which are involved in the proline metabolism pathway, played an important role in the drought tolerance of innovative alfalfa germplasm. Under water stress, with the regulation of key genes in the proline metabolism pathway, the proline content of all alfalfa lines increased to varying degrees. Among them, the proline content in the shoots and roots of transgenic line L6 was 7.29 times and 12.22 times that under normal irrigation conditions, respectively. The present study helped to clarify that the new germplasm of alfalfa transformed with the CsP5CDH gene synthesized a large amount of proline under water stress, and effectively slowed leaf water loss, thus improving the drought resistance of alfalfa.
Arm B Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush).Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 35 mg of TST infused over 30 minutes (inclusive of a 10-minute flush). Subjects randomized to Arm B were allowed to cross-over and receive TST/ I-131 TST once their disease had progressed.
Participants receive 400 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants that complete 9 cycles of pembrolizumab and experience biopsy-proven-disease recurrence may be eligible to receive up to 18 additional cycles of pembrolizumab in an open-label design.
This study takes place in the Divisions of Urology at Chang Gung Memorial Hospitals. Patients who have only received hormonal therapy will be enrolled. With reference to past research findings, self-efficacy theory, and experts' advice, a multimedia hormone therapy information program was developed. The multimedia hormone therapy information program covered 6 topics, namely the recognition of hormone therapy and multimedia information programs, mindfulness, exercise, stress relief, positive thinking, and prevention or reduction of fatigue. A pilot study will be conducted to check the feasibility of intervention study design and the effectiveness of the program will be tested. Patients will be randomly sorted into an experimental group (multimedia information group, n = 36 to 40) and a control group (routine care group, n = 36 to 40) after completing a pretest questionnaire. The experimental group will receive the multimedia information intervention once per week for 6 consecutive weeks, while the control group will receive routine care. The follow-up data collections will be completed at 8 and 12 weeks after the pretest. For quantitative measurement, the main variables will be social support, self-efficacy, quality of life, positive thinking, and satisfaction with program. Generalized Estimating Equations (GEEs) will be used to o analyze data.
This invention is based on efficacy of compounds and combination of compounds. Which essential for treatment of a number of diseases. These are pain, antiinfilamation, hepatoprotective, fever, allergy thereof. This combination has less toxicity, it has highly hepatotoxicity. The main mechanism of action of paracetamol is considered to be the inhibition of cyclooxygenase (COX) that it is highly selective for COX-2. The concentration of paracetamol is 500mg and thereof. Racemethionine is anti-oxidant nutritional supplement to treat liver diseases caused by alcoholism including cirrhosis. It acts as important sulphur and methyl group donor in detoxification reactions in liver cells. The concentration of racemethionine is 50mg and thereof. All effective cold remedies containing phenylephrine. The concentration of Phenylephrine is 5 mg/tablet and thereof. Phenylephrine to form an allergy medication with both antihistamine and decongestant properties. Chlorphenaminemaleate is suitable compound for cough and cold.chlorphenamine maleate to form an allergy medication with both antihistamine and decongestant properties. The concentration of chlorphenaminemaleate is 2 mg/tablet and thereof. Caffeine may also have hepatoprotective properties. Increased caffeine consumption is associated with less severe liver injury among those at high risk for liver disease, such as those with alcoholism, obesity, or hemochromatosis. The concentration of caffeine is 15 mg/tablet and thereof.
PROBLEM TO BE SOLVED: To decide the optimal dose per each time and the frequency of oral administration by judging the detectable concentration in urine through change in the dose per each time of an edible substance which is nontoxic, soluble in water, and can be excreted into urine (for example, vitamin C) at a physiologically beneficial level. SOLUTION: In the first step a previously set dose of a water-soluble, nontoxic, and edible composition, which can be excreted into urine (for example, an antioxidant or vitamin C) is given to a person at a previously set time. Then, urinary level of the composition is monitored for 24 hours following the administration time. These procedures are repeated until the threshold value of the dose per each time is found for manifesting sustainable increase in the urinary concentration of said compccsition for at least the prevtously setting period. Basing on the results, a dose per each time, not less than the found threshold value, is given to the person within the period for previous setting.  For example, if vitamin C is orally given by 500mg as a dose per each time every about 12 hours, vitamin C is maintained in the urea in average average healthy person at a continuously detectable level.
The present invention is inter alia directed to pharmaceutical compositions or vaccines comprising lipid-based carriers, wherein the lipid-based carriers comprise RNA and are contained in a buffer system that comprises at least one polyol component (e.g. glycerol), at least one sugar component (e.g. sucrose), and at least one buffer agent (e.g. Tris). The improved formulations advantageously stabilize the lipid-based carriers comprising the RNA during storage (e.g. at 5°C and/or -20°C). Further aspects inter alia relate to methods of manufacturing, methods for stabilization, and various uses. Also provided are methods of treating or preventing disorders or diseases, and first, second, and further medical uses.
Participants will ingest a placebo solution (27 doses over 14 days) formulated to approximate the taste of diazoxide oral suspension. Blinding will occur by completely covering single-dose oral syringes with labels.
PURPOSE: A composition containing blackchokeberry extract is provided ensure anti-angiogenesis and to prevent and treat diseases relating to angiogenesis without side effects. CONSTITUTION: An angiogenesis inhibitor contains blackchokeberry extract as an active ingredient. The blackchokeberry extract contains anthocyanin. The blackchokeberry extract comprises 64.5% of 3-O-galactoside cyanidine, 28.9% of 3-O-arabinoside cyanidine, 4.2% of 3-O-xyloside cyanidine, and 2.4% of 3-O-glucoside cyanidine. The inhibitor is used in treating and preventing cancer, rheumatic arthritis, psoriasis or diabetic retinopathy. A composition for preventing and treating cancer contains blackchokeberry extract as an active ingredient. The composition is used in the form of pill, capsule, drink and medicinal and pharmaceutical product.
Treatment seeking adolescent patients with a moderate to severe major depressive episode defined as a 40 or greater on Childhood Depression Rating Scale-Revised (CDRS-R) will be invited to participate in this study evaluating the GeneSight® platform. This new technology can rapidly assess PK and PD genetic variation that can potentially impact antidepressant, anti-psychotic, and stimulant treatment selection. These patients will have GeneSight® testing and will be randomized to one of two groups. In Group 1 (n=138), GeneSight® testing results will be available to the patient's treating clinician prior to treatment selection. In Group 2 (n=138), testing results will not be available to the patient's research treating clinician. However, all testing results will be made available to all participants and clinicians after the 8-week trial (upon completion of blinded assessments at week 8). The patients and the clinical raters will be blinded to group assignment.
PURPOSE:A drug for improving diabetic osteoporosis, containing 24,25- dihydroxycholecalciferol as an active ingredient. CONSTITUTION:The titled drug containing 24,25-dihydroxycholecalciderol [24,25-(OH)2-D3 for short] as an active ingredient. It is unclear that the true form of diabetic bone reducing disease is osteoporosis, bone osteomalacia, or change in bone specific to diabetes, and many parts are unclear about its causing factors. In an experiment using diabetic model rats, it is found that 24,25-(OH)2-D3 has an inhibitory action on reduction in Ca in bone of diabetic rats, and improving action on diabetic bone reducing disease. This substance may be 24R,25-(OH)2-D3, 24R,25-(OH)2-D3, or their mixture, and 24R,25-(OH)2-D3 is especially preferable. A dose for adult is 0.1mug-1X10<5>mug/day, and the drug may be administered orally or parenterally.
Drugs metabolized by cytochrome P450 2D6 (CYP2D6): Sensipar® is a strong in vitro, as well as in vivo, inhibitor of CYP2D6. Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 (eg, metoprolol and carvedilol) and particularly those with a narrow therapeutic index (eg, flecainide, vinblastine, thioridazine and most tricyclic antidepressants) may be required.

Desipramine: Concurrent administration of cinacalcet (90 mg) with desipramine (50 mg) increased the exposure of desipramine by 3.6 fold in CYP2D6 extensive metabolizers. 

Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.

Midazolam: There were no significant differences in the pharmacokinetics of midazolam, a CYP3A4 and CYP3A5 substrate, in subjects receiving 90 mg cinacalcet once daily for 5 days and a single dose of 2 mg midazolam on day 5 as compared to those of subjects receiving 2 mg midazolam alone. This suggests that cinacalcet would not affect the pharmacokinetics of drugs predominantly metabolized by CYP3A4 and CYP3A5.